NeuroMetrix stock soars over pain device distribution deal; Third Rock Ventures on a roll;

@FierceMedDev: Biocept Laboratories becomes latest Dx outfit to explore IPO. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Medtronic won expanded indications for one of its key vascular stents. Release | Article | Follow @MarkHFierce

> Edwards Lifesciences ($EW) priced $600 million of senior notes that will, in part, help repay debt. Item

> NeuroMetrix ($NURO) saw its stock soar late Tuesday after announcing a distribution deal with a national diabetes mail-order supply company for its new pain-management device. Story

> Labcyte will work with AstraZeneca ($AZN) to use acoustic sample handling for mass spectrometry to advance drug discovery. Item

> Oraya Therapeutics reports positive two-year safety data for its Oraya therapy, which uses low-energy, highly targeted X-rays to treat wet age-related macular degeneration. Item

> Australian researchers found that an insulin pump that automatically stopped pumping helped reduce serious hypoglycemia in patients with high-risk Type 1 diabetes. Story

> Illumina ($ILMN) is applying the CE mark toward expanded lab use of technology that facilitates the development of diagnostic tests. Item

> Nature profiles the founders of Third Rock Ventures, backers of life sciences companies including Foundation Medicine, the cancer diagnostics outfit that just went public with a $106 million IPO. Story

Biotech News

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | FierceBiotech's 2013 Fierce 15 | Follow @FierceBiotech

@JohnCFierce: Merck KGaA doubles down on Oncothyreon's failed cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Apparently no one wanted to spend ~$3B on Clovis Oncology. Perhaps Big Pharma wants its biotechs to generate revenue. Story | Follow @DamianFierce

@EmilyMFierce: Stem cell reprogramming made easier by removing one protein. Popular yesterday from FierceBiotech Research | Follow @EmilyMFierce

> Plotting Asia expansion, Amgen blueprints plans for Shanghai research center. More

> Ophthotech, Foundation Medicine loot booming biotech IPO market for $273M. Article

Pharma News

@FiercePharma: Lundbeck's refusal to sell pentobarbital to prisons hits Ohio's execution plans. More from Reuters | Follow @FiercePharma

@EricPFierce: FDA warning letter for Strides Arcolab Agila Specialties plant arrives. Mylan not too concerned. Story from FiercePharmaManufacturing | Follow @EricPFierce

> Cost gatekeepers give final 'no' to Pfizer's targeted cancer drug Xalkori. Report

> Eli Lilly's diabetes strategy doesn't include big staff-up in sales. Article

Drug Delivery News

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. Story | Follow @MichaelGFierce

> Study: Artificial pancreas with inhaled insulin improves glucose control. More

> Alnylam heralds positive results for RNAi amyloidosis drug. Article

> Surefire collects $16.4M to expand cancer-drug catheter biz. Item

> Bind collects $70.5M IPO to support Accurin tech. Story

Diagnostics News

> Cognoptix Alzheimer's eye test generates robust trial results. Article

> Alzheimer's diagnosis may gain from PET imaging of tau proteins. Report

> Case Western, GSK find promise with MS diagnostic 'probe.' Story

> In vitro Dx to remain at top of med tech heap. More

> Cigna: Genetic counseling mandates will come for other Dx tests. Article